The Twice Yearly HIV Shot Rolling Out Across Southern Africa

South Africa's health department says tens of thousands of people have now started a twice yearly HIV shot that replaces the daily prevention pill, marking the fastest uptake of a new HIV prevention method the country has seen in years. The medicine, lenacapavir, is given as an injection just twice a year after initial doses, and according to South Africa's Department of Health it had been initiated by 55,123 people across the country's public clinics as of early September 2026. Most of them — 71 percent — are women, with pregnant and breastfeeding mothers forming a large share of early recipients, as reported by EIN Presswire.

The rollout is not stopping at South Africa's borders. Zambia launched its own programme at the start of September 2026 with the goal of reaching 82,000 people across 542 health facilities before the year ends, backed by UNAIDS, the Global Fund, and the United States government. About 21,000 of those expected recipients are pregnant or breastfeeding women, a group where preventing new infections also protects babies. Zimbabwe, meanwhile, is preparing a nationwide scale-up of its twice yearly HIV shot programme in January, with a first batch of 23,000 doses already in the country and health workers in training, as reported by fundsforNGOs.

For a region that still carries the heaviest share of new HIV infections worldwide, the arrival of a twice-a-year option is a genuine turning point in prevention.

How the twice yearly HIV shot got here

The medicine's journey from trial to township clinic moved unusually fast. The United States Food and Drug Administration approved lenacapavir for prevention in June 2025, and Europe's medicines agency issued a positive opinion the following month. In July 2025 the World Health Organization released its first guidelines on the injectable, and on 6 October 2025 WHO prequalified it — a step that opened the door for UN agencies and global health partners to buy it for poorer countries, according to WHO. South Africa's regulator approved the product later that same month, and Zambia and Zimbabwe followed that November through a fast-track reliance procedure.

President Cyril Ramaphosa and Health Minister Aaron Motsoaledi formally launched the South African programme on 5 June 2026, offering the injection through 360 public health facilities across 24 districts in six provinces. Gauteng, the province that includes Johannesburg and Pretoria, accounts for roughly half of all initiations so far, with KwaZulu-Natal next. Zambia's launch at Lusaka's University Teaching Hospital followed later that month. Each step in that chain compressed a process that usually takes years into months — a sign of how seriously health authorities treat the promise of a prevention method that asks so little of the people using it.

Why the twice yearly HIV shot matters for young people

The daily prevention pill works, but only if you take it every single day. South Africa has started more than two million people on daily oral PrEP since 2016, yet pill fatigue, stigma, and the need for constant clinic access make it hard for many to stay on it. Young women in particular face a tangle of barriers: a bottle of pills is visible to family and partners, a daily dose is easy to miss, and stopping for even a few weeks leaves someone unprotected. The twice yearly HIV shot changes that equation. Two clinic visits a year is a far smaller ask than 365 doses, and an injection leaves no pill bottle to explain.

The trial evidence behind the medicine is some of the strongest HIV prevention science has ever produced. In the PURPOSE 1 trial, the injection prevented nearly all new infections among adolescent girls and young women — a population at the center of southern Africa's epidemic. The drug works by blocking the virus's capsid, the shell it needs to copy itself, and it stays active in the body for months from a single subcutaneous injection. That long-acting profile is exactly why health officials talk about it as a tool for people who found the daily pill hard to fit into real life.

For Gen Z readers, the practical takeaway is simple: the twice yearly HIV shot means HIV prevention no longer has to mean a daily reminder of risk. Whether through a university clinic, a community health center, or a national programme like the ones expanding across southern Africa, prevention is moving toward options that fit around busy, privacy-conscious lives rather than demanding they reorganize around a pill schedule. If you are sexually active and HIV is a concern, it is worth asking a clinician what prevention choices are available where you live — the menu is growing, and this injection is now on it.

The access fight that still surrounds the twice yearly HIV shot

The science is not the hard part anymore; getting the medicine to everyone who needs it is. In the United Kingdom, access has stalled: a draft decision from the health technology assessor NICE put the cost-effectiveness estimates above the acceptable range for prevention use, and campaigners have warned the delay could push the world's first twice-yearly option out of reach for many in Britain, as reported by Life Science Daily. Pricing debates have shadowed the drug since its approval, with the manufacturer agreeing to supply it at cost to lower-income countries while higher-income health systems negotiate over what they should pay.

Global funding cuts add to the pressure. The AIDS Vaccine Advocacy Coalition estimates that around two and a half million people lost access to PrEP in 2025 because of donor funding disruptions, a setback that makes affordable rollouts like Zambia's and South Africa's harder to sustain. WHO has urged countries to pair the new tool with decisive action and community engagement, warning that the goal of ending AIDS by 2030 slips further away when prevention stalls for lack of money.

That tension — breakthrough science on one side, budgets and bureaucracy on the other — is the story to watch. Southern Africa is showing what rapid, well-supported rollout of the twice yearly HIV shot can look like: trained health workers, alternative delivery points beyond conventional clinics, and demand that outpaces the first consignments. Zambia reported that its first doses were taken up within weeks, forcing officials to adjust distribution so people who started could get their second shot on time. If the momentum holds, the twice yearly HIV shot could become the decade's defining step in HIV prevention — but only if access keeps pace with the evidence. For more on sexual health coverage, see GenZ NewZ's sexual wellness topic page and our related report PrEP Uptake After STI Diagnosis Doubles in Atlanta Patients.